-
1 month ago | 
uscjournal.com | Harold Bays |Naveed Sattar |Gurleen Kaur |Saman Nematollahi
Average (ratings) Abstract With the dawn of advanced technological and digital resources, medical education has changed. Learners are now able to learn, share, and communicate medical knowledge through online discussion forums, blogs, videos, podcasts, infographics, virtual communities, social media platforms, and collaborative author groups. Navigating these digital education modalities can be challenging, with each platform presenting unique challenges and opportunities.
-
Aug 10, 2024 | 
nature.com | Fanny Petermann-Rocha |John C. Mathers |Carlos Celis-Morales |Naveed Sattar |Jill P Pell
AbstractIt is elusive why some heavy drinkers progress to severe alcohol-related liver disease (ALD) while others do not. This study aimed to investigate if the association between alcohol consumption and severe ALD is modified by diet. This prospective study included 303,269 UK Biobank participants. Alcohol consumption and diet were self-reported. The diet score was created from 4 items selected using LASSO.
-
Jul 31, 2024 | 
heart.bmj.com | Harlan M. Krumholz |Naveed Sattar |Bruno Linetzky |Palash Sharma
DiscussionIn the SURMOUNT-1 trial, in addition to substantial body weight reduction, tirzepatide demonstrated robust and sustained BP lowering in people with overweight or obesity over 72 weeks of treatment. Tirzepatide lowered SBP and DBP over the first 24 weeks, followed by maintenance through 72 weeks. By the end of the study, tirzepatide led to a 6.8 mm Hg lower mean SBP than placebo and a 4.2 mm Hg lower DBP.
-
Jul 19, 2024 | 
nature.com | Zhila Semnani-Azad |Mario L. Morieri |John Dennis |Claudia Langenberg |Michèle Ramsay |Arun J Sanyal | +6 more
AbstractPrecision medicine should aspire to reduce error and improve accuracy in medical and health recommendations by comparison with contemporary practice, while maintaining safety and cost-effectiveness. The etiology, clinical manifestation and prognosis of diseases such as obesity, diabetes, cardiovascular disease, kidney disease and fatty liver disease are heterogeneous.
-
May 29, 2024 | 
radcliffecardiology.com | Harold Bays |Sven Francque |Donna Ryan |Naveed Sattar
Video Published: Views: 34 Likes: 0 Average (ratings) ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk). This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes.
-
May 25, 2024 | 
nature.com | Naveed Sattar
Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them — particularly once market competition makes these drugs more accessible.
-
May 20, 2024 | 
ahajournals.org | Naveed Sattar |Ian J. Neeland |Darren K. McGuire
Just 40 years ago, the prevalence rate of obesity in most high-income countries was <5% to 10%, whereas the prevalence rates of smoking, high blood pressure and high cholesterol levels were much higher. Consequently, rates of myocardial infarction and stroke were substantially higher, and most patients diagnosed with heart failure (HF) had a short life expectancy, many succumbing to disease-related cachexia (Figure).
-
Apr 17, 2024 | 
jamanetwork.com | Louis J. Aronne |Naveed Sattar |Deborah Horn |Harold Bays
Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity—Reply Effect of Tirzepatide on Maintenance of Weight Reduction Louis J. Aronne, MD; Naveed Sattar, MD; Deborah B. Horn, DO, MPH; Harold E. Bays, MD; Sean Wharton, MD; Wen-Yuan Lin, MD, PhD; Nadia N. Ahmad, MD, MPH; Shuyu Zhang, MSc; Ran Liao, PhD; Mathijs C. Bunck, MD, PhD; Irina Jouravskaya, MD, PhD; Madhumita A.
-
Apr 1, 2024 | 
onlinelibrary.wiley.com | Naveed Sattar |Javed Butler |Baylor Scott |Matthew Lee
Introduction Excess adiposity (overweight or obesity) is a risk factor for heart failure (HF), and represents a potentially distinct phenotype in HF with preserved ejection fraction (HFpEF); of course, lower body mass index (BMI) levels also predict adverse outcomes in prevalent HF.1 Obesity (defined as BMI ≥30 kg/m2) is highly prevalent in trials of patients with HFpEF (e.g. 45% in EMPEROR-Preserved,2 49% in PARAGON-HF,3 55% in TOPCAT,4 41% in I-PRESERVE5).
-
Mar 8, 2024 | 
dom-pubs.onlinelibrary.wiley.com | Bjorn Eliasson |Naveed Sattar |Katie Harris |Mark Woodward
1 INTRODUCTION Individuals with type 1 diabetes have an increased risk of developing cardiovascular disease (CVD, defined as myocardial infarction, stroke and fatal CVD) compared to the general population, with risks elevated 2.3-fold in women and threefold in men.1, 2 The first signs of accelerated vascular harm have been shown to already appear during adolescence in individuals with type 1 diabetes.3 Efforts to mitigate risk factor exposure, including glycaemic control, should ideally start...
